Epstein-Barr Virus-Specific CD8 T Cells Selectively Infiltrate the Brain in Multiple Sclerosis and Interact Locally with Virus-Infected Cells: Clue for a Virus-Driven Immunopathological Mechanism

Barbara Serafini, Barbara Rosicarelli, Caterina Veroni, Gina Adriana Mazzola, Francesca Aloisi

ABSTRACT

Epstein-Barr virus (EBV) is a ubiquitous herpesvirus strongly associated with multiple sclerosis (MS), a chronic inflammatory disease of the central nervous system (CNS). However, the mechanisms linking EBV infection to MS pathology are uncertain. Neuropathological and immunological studies suggest that a persistent EBV infection in the CNS can stimulate a CD8 T-cell response aimed at clearing the virus but inadvertently causing CNS injury. Inasmuch as in situ demonstration of EBV-specific CD8 T cells and their effector function is missing, we searched for EBV-specific CD8 T cells in MS brain tissue using the pentamer technique. Postmortem brain samples from 12 donors with progressive MS and known HLA class I genotype were analyzed. Brain sections were stained with HLA-matched pentamers coupled with immunogenic peptides from EBV-encoded proteins, control virus (cytomegalovirus and influenza A virus) proteins, and myelin basic protein. CD8 T cells recognizing proteins expressed in the latent and lytic phases of the EBV life cycle were visualized in white matter lesions and/or meninges of 11/12 MS donors. The fraction (median value) of CD8 T cells recognizing individual EBV epitopes ranged from 0.5 to 2.5% of CNS-infiltrating CD8 T cells. Cytomegalovirus-specific CD8 T cells were detected at a lower frequency (≤0.3%) in brain sections from 4/12 MS donors. CNS-infiltrating EBV-specific CD8 T cells were CD107a positive, suggesting a cytotoxic phenotype, and stuck to EBV-infected cells. Together with local EBV dysregulation, selective enrichment of EBV-specific CD8 T cells in the MS brain supports the notion that skewed immune responses toward EBV contribute to inflammation causing CNS injury.

IMPORTANCE

EBV establishes a lifelong and asymptomatic infection in most individuals and more rarely causes infectious mononucleosis and malignancies, like lymphomas. The virus is also strongly associated with MS, a chronic neuroinflammatory disease with unknown etiology. Infectious mononucleosis increases the risk of developing MS, and immune reactivity toward EBV is higher in persons with MS, indicating inadequate control of the virus. Previous studies have suggested that persistent EBV infection in the CNS stimulates an immunopathological response, causing bystander neural cell damage. To verify this, we need to identify the immune culprits responsible for the detrimental antiviral response in the CNS. In this study, we analyzed postmortem brains donated by persons with MS and show that CD8 cytotoxic T cells recognizing EBV enter the brain and interact locally with the virus-infected cells. This antiviral CD8 T cell-mediated immune response likely contributes to MS pathology.

KEYWORDS

brain, cytotoxicity, EBV-specific CD8 T cells, Epstein-Barr virus, immunopathology, multiple sclerosis
Multiple sclerosis (MS) is the most common chronic inflammatory disease of the central nervous system (CNS) and the leading cause of nontraumatic neurological disability in young adults. Leukocyte infiltration, demyelination, neurodegeneration, and reactive gliosis in the CNS are the histopathological hallmarks of MS, leading to progressive deterioration of motor, sensory, and cognitive functions (1). The precise etiology of MS and whether it is self or nonself antigens that trigger persistent CNS inflammation is not yet clear. The current belief is that MS develops in a genetically susceptible host upon interaction with environmental factors (2). More than 200 susceptibility genes have been identified, with the HLA DRB1*1501 allele conferring the strongest risk for MS (3). The most common environmental risk factors are sunlight exposure/vitamin D level, cigarette smoking, and infectious agents (2). Among the latter, Epstein-Barr virus (EBV), a human DNA herpesvirus infecting about 95% of the adult population worldwide, is the main candidate culprit; no other pathogen shows such a strong association with MS (4, 5).

EBV infection commonly occurs early in life, is asymptomatic, and is carried as a latent, lifelong infection of B cells that is tightly controlled by the host’s immune system (6). However, in some circumstances the virus-host balance is disturbed and the pathogenic potential of EBV can manifest. EBV is etiologically linked to a variety of human tumors, including lymphomas and nasopharyngeal carcinoma, and to diseases like infectious mononucleosis, the genetically acquired X-linked lymphoproliferative disease, and chronic active EBV infection, which are caused by exaggerated immune responses to the virus resulting in bystander tissue damage (7).

The association of EBV with MS is mainly supported by large-scale studies that have consistently shown virtually 100% EBV seroprevalence in adult MS, higher anti-EBV antibody titers, particularly for EBNA1 IgG, in MS patients than in healthy subjects (5, 8–10), and an increased risk of developing MS after infectious mononucleosis (11). It has been shown that EBV infection is required for MS development (12) and that the rise in anti-EBV antibody titers occurs already several years (up to 20) before MS diagnosis (13–15), suggesting a causative role of EBV in MS. Elevated CD4 and CD8 T cell responses to EBV in MS patients, particularly during disease flares, are consistent with abnormal EBV infection in MS (16–20). Studies have also shown impaired EBV-specific CDS T cell responses in MS patients (21–23) and a decreased frequency or functionality of EBV-specific CD8 T cells with increasing disease duration (18, 22, 23), suggesting T-cell exhaustion due to a persistently active infection. Since EBV establishes latency in memory B cells (6), confirmation of the beneficial effects of B-cell-depleting anti-CD20 monoclonal antibodies (MAbs) in large MS cohorts (24, 25) has reinforced the association between EBV and MS and the need for studies to elucidate the mechanisms linking EBV infection to MS pathology (26, 27).

Molecular mimicry between viral and CNS myelin antigens (28, 29) and EBV-mediated induction of a putative autoantigen, the small stress protein alpha B-crystallin (30), have been proposed as possible mechanisms underlying the EBV-MS link. However, the available evidence is still inconclusive. Immortalization of autoreactive B cells by EBV remains hypothetical (31), especially when one takes into account the unproven role of autoantibodies in MS and the fact that the rapid clinical effect of B-cell-depleting drugs in MS is not accompanied by a reduction in antibody production and intrathecal Ig synthesis (32). This rules out the involvement of humoral immunity in the therapeutic effect. Evidence also is missing that EBV is preferentially harbored in autoreactive B cells (33). Another possibility is that impaired immune responses to EBV at primary infection results in increased viral load (34), allowing migration of activated, circulating EBV-infected B cells into the CNS. Due to its ability to stimulate B-cell proliferation (6), EBV would promote intrathecal B-cell expansion and maturation, a hallmark of MS (1). A CNS-secluded, low-grade, and chronically active EBV infection would stimulate an immune response that promotes inflammation and inadvertently causes damage to the CNS (7). This pathogenic model is supported by our studies in postmortem MS brain tissue showing a dysregulated, predominantly latent EBV infection in CNS-infiltrating B cells, particularly those forming ectopic B-follicle-like structures in the meninges.
(35–38), and viral reactivation in CNS-infiltrating plasmablasts/plasma cells (19, 35, 38).
EBV latent and lytic transcripts were also detected in laser-cut CNS immune infiltrates
(19, 36, 39). Most importantly, we have shown that EBV dysregulation in the CNS is
characteristic of MS and is not observed in patients with other infectious and noninfectious
inflammatory diseases of the CNS (35, 36). Abnormal EBV infection in the MS
brain has been confirmed in other independent studies (40–42), while several researchers
failed to detect EBV in MS brain lesions (43–46). Such discrepancies across studies
may be explained by differences in sample selection and methods/tools to detect EBV
(47, 48).

Although an EBV-induced immunopathological model of MS is biologically plausibly,
it needs to be substantiated by a more detailed understanding of the immune
components involved. Cytotoxic CD8 T cells play an important role in controlling EBV
infection (49), and it is well established that CD8 T cells represent the predominant
T-cell population in MS brain inflammatory lesions (50, 51). It was also shown that MS
brain-infiltrating CD8 T cells undergo clonal expansion (52) and express a cytotoxic
effector phenotype (19, 35, 38, 53) indicating in situ activation. Several studies have
demonstrated selective enrichment of EBV-specific CD8 T cells but not CD8 T cells
recognizing cytomegalovirus (CMV) or candidate MS-associated autoantigens, in the
cerebrospinal fluid (CSF) of MS patients (54–57), suggesting activation of a localized
cytotoxic T-cell response toward EBV.

Despite intimate contacts between cytotoxic CD8 T cells and EBV-infected cells
being visualized in the MS brain (19, 35, 38, 58), direct demonstration of the presence
and effector function in situ of EBV-specific CD8 T cells is missing. This issue can be
tackled by using fluorochrome-labeled, major histocompatibility complex (MHC) class I
peptide multimers (tetramers or pentamers), which allow the distinguishing of antigen-specific
from total CD8 T cells in appropriately processed human tissues (59–61). In this
study, we used postmortem brain tissue donated by persons with MS and in situ pentamer staining to (i)
characterize the EBV antigens recognized by CNS-infiltrating CD8 T cells, (ii) compare the frequency of EBV-specific CD8 T cells with that of CD8 T
cells recognizing other common viruses or a putative myelin autoantigen, and (iii) study the
cytotoxic effector function of CNS-infiltrating, EBV-specific CD8 T cells and their
spatial proximity to virus-infected B cells/plasma cells.

RESULTS

Neuropathological characteristics of MS brain samples and visualization of
EBV-specific CD8 T cells in brain sections. Fresh-frozen brain samples from 12 MS
donors carrying common HLA-A (A*0201) and/or HLA-B (B*0702, B*0801) alleles (Table
1) were used to perform in situ stainings with MHC class I pentamers coupled to
immunodominant peptides from EBV-encoded latent and lytic proteins, CMV and
influenza A virus proteins as controls, and the candidate MS autoantigen myelin basic
protein (MBP) (Table 2). In order to increase the chance of detecting virus-specific CD8
T cells, the brain tissue blocks analyzed in this study included immunologically active
white matter (WM) lesions (active and chronic active lesions) and/or intact meninges
containing substantial numbers of infiltrating CD8 T cells and B cells (Fig. 1A to G).
Based on our published (19, 35–39) and unpublished data, all selected MS brain
samples contained EBV-infected cells, as revealed by in situ hybridization for the EBV
noncoding small RNA EBER (35, 37), immunohistochemistry for EBV proteins (19,
35–38), and/or real-time reverse transcription-PCR (19, 36, 39). Figure 1 shows cells
expressing EBER (Fig. 1H and I), the EBV latency III protein EBNA2 (Fig. 1J), the latency
II proteins LMP1 and LMP2A (Fig. 1K to M), and the EBV immediate-early lytic protein
BZLF1 (Fig. 1O), as well as CD79a+ B cells expressing LMP1 (Fig. 1N) and Ig-producing
plasma cells expressing BZLF1 (Fig. 1P), in brain samples from three of the 12 MS donors
analyzed. Quantification of CD8 T cells in the MS brain sample cohort is shown in Fig.
1Q; the number of CNS-infiltrating cells stained with anti-CD8 MAb ranged between
130 and 2,200 (median value, 675) per brain section.
In preliminary experiments, we aimed to find out whether EBV-reactive T cells could be visualized in situ and belonged to the CD8 T cell population. To this end, immunodominant B*0801/H5009-restricted responses toward the EBV latent protein EBNA3A and the EBV lytic protein BZLF1 (62, 63) were investigated. Serial brain sections from four HLA B*0801/H11001 MS donors were stained with anti-CD8 MAb and B*0801 pentamers coupled with EBNA3A- and BZLF1-derived peptides (Table 2). Staining of MS brain sections with HLA class I-mismatched pentamers was also performed to check the specificity of pentamer binding. Bright-field immunohistochemistry revealed that isolated or clustered EBV pentamer-binding cells were intermingled with the more numerous anti-CD8 MAb-binding cells in perivascular immune infiltrates localized within or close to active white matter lesions (Fig. 2A to F) and in the meninges (not shown). Cells binding EBNA3A or BZLF1 peptide-coupled pentamers were present in brain sections from all four HLA B*0801 MS donors, while no pentamer-binding cells were observed when adjacent sections were stained with A*0201 (Fig. 2G) or B*0702 (data not shown) pentamers.

To validate the binding of pentamers to CD8 T cells in MS brain sections, we performed double immunofluorescence stainings with anti-CD8 MAb and B*0801/BZLF1 or B*0801/EBNA3A pentamers. As depicted in Fig. 3, binding of EBNA3A (Fig. 3A) and BZLF1 (Fig. 3B to E) pentamers was restricted to CD8 T cells in brain sections from the four B*0801 MS donors analyzed, confirming the specificity and reliability of the observed stainings.

### TABLE 1  HLA class I allele restriction and demographic and clinical data of MS brain tissue donors

| Donor ID<sup>a</sup> | Donor HLA class I allele(s) | Sex/age at death<sup>b</sup> (yr) | Age at onset (yr) | Disease duration (yr) | Therapy<sup>c</sup> | Cause of death<sup>d</sup> | Postmortem delay (h) |
|---------------------|-----------------------------|-------------------------------|-----------------|-----------------------|-------------------|---------------------------|---------------------|
| MS79                | A*0201                      | F/49                          | 25              | 24                    | Courses of ACTH, azathioprine, and methylprednisolone over 2 yr | MS                  | 7                   |
| MS92                | B*0801                      | F/37                          | 20              | 17                    | None reported     | MS                        | 26                  |
| MS121               | B*0801                      | F/49                          | 35              | 14                    | Methylprednisolone for 1 yr | MS                  | 24                  |
| MS154               | B*0801                      | F/35                          | 23              | 12                    | None reported     | MS                        | 12                  |
| MS180               | B*0801                      | F/44                          | 26              | 18                    | None reported     | MS                        | 9                   |
| MS234               | B*0801                      | F/39                          | 24              | 16                    | None reported     | MS                        | 15                  |
| MS286               | A*0201                      | M/46                          | 30              | 16                    | None reported     | MS                        | 7                   |
| MS289               | A*0201, B*0702              | M/45                          | 27              | 18                    | None reported     | MS                        | 9                   |
| MS330               | B*0702                      | F/59                          | 20              | 39                    | None reported     | MS                        | 21                  |
| MS342               | A*0201, B*0702              | F/35                          | 30              | 5                     | None reported     | MS                        | 9                   |
| MS352               | B*0801                      | M/43                          | 25              | 18                    | Methylprednisolone and alemtuzumab (one course each) 10 yr before death | MS                  | 26                  |
| MS356               | B*0702                      | F/45                          | 29              | 16                    | None reported     | MS                        | 10                  |

<sup>a</sup>All MS donors were in the progressive phase of the disease.
<sup>b</sup>F, female; M, male.
<sup>c</sup>ACTH, adrenocorticotropic hormone.
<sup>d</sup>MS is stated as a cause of death where death occurred as a direct result of MS or any related disability.

MS brain-infiltrating EBV-specific CD8 T cells recognize viral proteins expressed in different phases of viral infection. We next searched and quantified EBV-reactive CD8 T cells in all brain samples included in this study (18 brain tissue blocks from 12 MS donors) using HLA-A*0201, B*0702, and B*0801 pentamers conjugated with identified immunodominant peptides from nine viral proteins expressed in different phases of the EBV life cycle: EBNA3A and EBNA3C (latency III or growth program), LMP1 and LMP2 (latency III and latency II programs), BZLF1 and BRLF1 (immediate-early lytic cycle), BMLF1 and BMRF1 (early lytic cycle), and BALF4 (late lytic cycle) (Table 2). Cells binding EBV pentamers were visualized in bright field in brain sections from 11 MS donors (16 tissue blocks); two brain samples from one HLA-A*0201+ donor (MS286) did not bind any of 5 different A*0201/EBV peptide-coupled pentamers or any other control pentamer (Table 3). These samples were among the less infiltrated (Fig. 1Q) and were excluded from the statistical analysis.

In the sample cohort displaying EBV pentamer binding, CD8 T cells to individual EBV peptides were visualized in all or the majority of tissue blocks analyzed (median, 100%;
| MS donor HLA class I alleles suitable for in situ pentamer binding and MS donor ID | EBV protein/epitope coordinates | EBV epitope sequence | CMV protein/epitope coordinates | CMV epitope sequence | Influenza A protein/epitope coordinates | Influenza A epitope sequence | MBP epitope coordinates | MBP epitope sequence |
|---|---|---|---|---|---|---|---|---|
| **A*0201** | MS79, MS286, MS289, MS342 | EBNA3C/284–293 LMP1/125–133 LMP2/356–364 LMP2/426–434 BRLF1/109–117 BMLF1/259–267 BALF4/276–284 | LLDFVRFMGV YLEMLWRL FLYALALLL CLGGLTMV YVIHDHLVV GLCTLVAML FLDKGTYTL | pp 65/495–504 | NLVPMVATV | MP/58–66 | GILGFVFTL | 110–118 | SLSRFSWGA |
| **B*0702** | MS289, MS330, MS356, MS342 | EBNA3A/247–255 EBNA3C/881–889 BMRF1/116–128 | RPIFIIRRL QPRAPIRPI RPQGGSPEFVKL | pp 65/265–275 | RPHERNGFTVL NP/473–481 | SPIVPSFDI | |
| **B*0801** | MS92, MS121, MS154, MS180, MS234, MS352 | EBNA3A/193–201 BZLF1/190–197 | FLRGRAYGL RAKFXQLL | IE 1/88–96 | QIKVRVDMV | | | | |
FIG 1 Neuropathological characteristics, EBV infection, and CD8 T cell infiltration in the MS brain. Stainings of brain sections from 3 MS donors included in this study are shown. (A to D, donor MS121) Actively demyelinating WM lesion characterized by myelin loss (A, MOG immunostaining), foamy macrophages (B, CD68 immunostaining), and prominent CD8 T cell infiltration (C, CD8 immunostaining). A large perivascular cuff with high-density B cells and CD8 T cells is shown (D, double immunofluorescence for CD20 [green] and CD8 [red]). (E to G, donor MS79) Immune cell infiltrate (E, H&E staining) and CD8 T cells (F) in the meninges; double immunostaining for CD20 (green) and CD8 (red) reveals numerous CD8 T cells clustered around B cells in the meningeal infiltrate (G). (H to N, donor MS121) EBV-infected cells are visualized using EBER in situ hybridization; numerous EBER+ nuclei in the infiltrated meninges and in a perivascular cuff of a chronic WM lesion are shown (H and I, respectively). (J) Immunohistochemistry with anti-EBNA2 Ab reveals occasional perivascular cells expressing the latency III protein EBNA2 in a WM lesion. Double immunofluorescence stainings for LMP1 (green) and LMP2A or the B cell (Continued on next page)
range, 67 to 100%). The CD8 T cells specific for EBV latent and lytic proteins (Fig. 4 and 5, respectively) were observed in the infiltrated meninges and/or within perivascular cuffs of small to large size in active WM lesions and at the active edge of chronic WM lesions. In two donors (MS234 and MS289), both CD8-expressing cells and EBV-specific CD8 T cells were also found scattered throughout active WM lesions (Fig. 5I, J, N, and O).

The frequency of CD8 T cells recognizing individual EBV protein-derived peptides was calculated by dividing the number of pentamer-binding cells counted in the entire brain section by the number of cells stained with anti-CD8 MAb in an adjacent section. For each EBV peptide analyzed, there was high variability in the frequency of pentamer-binding cells visualized in brain sections from different donors or from different brain tissue blocks of the same donor (Table 3 and Fig. 6A). The percentage (median value) of EBV peptide-specific CD8 T cells ranged between 0.5 and 2.5% of the total CD8 cell population (Fig. 6A). Frequencies above 3% (up to 4.5%) were found only in brain sections stained with pentamers coupled with peptides from the latency III protein EBNA3C, the immediate-early protein BZLF1, and the early lytic proteins BMLF1 and BMRF1 (Table 3 and Fig. 6A). Using the Kruskal-Wallis test, no significant differences were found in the frequency of CD8 T cells recognizing EBV latency or lytic cycle-related proteins. Collectively, however, CD8 T cells recognizing EBV lytic antigens tended to be more frequent than those recognizing EBV latent proteins (Fig. 6B). Only in the HLA-B*0801+ sample subgroup (8 brain samples from 6 MS donors) was the frequency

![CD8 T-Cell Response to EBV in Multiple Sclerosis](jvi.asm.org)
of CD8 T cells recognizing BZLF1 significantly higher than that of CD8 T cells recognizing EBNA3A (Fig. 6C).

The frequency of EBV-specific CD8 T cells raised to 12 to 19% when the frequencies of CD8 T cells reactive to different EBV peptides in serial brain sections from the same tissue block were summed and to 8 to 9% when brain sections were incubated with a mixture of two EBV pentamers (i.e., B*0801/EBNA3A and B*0801/BZLF1) (Table 3 and

FIG 3 Validation of EBV pentamer binding to CD8 T cells in brain sections from HLA-B*0801† MS donors. Double immunofluorescence stainings with anti-CD8 MAb (green, left column) and B*0801/EBNA3A or B*0801/BZLF1 pentamers (red, middle column) were performed in brain sections from four HLA-B*0801† MS donors (MS234 [A], MS92 [B], MS121 [C], and MS180 [D and E]). Merge of CD8 and pentamer stainings (right column) reveals colocalization of CD8 immunoreactivity and pentamer binding in a subpopulation of CD8 T cells infiltrating the WM (A, C, and D) and the meninges (B and E); the arrows indicate double-labeled cells. Nuclei were stained with DAPI. Bars, 20 μm.
### TABLE 3
Percentages of CD8 T cells recognizing EBV, CMV, influenza A virus, and MBP protein-derived peptides in the total CD8 T-cell population infiltrating the MS brain

| Donor ID and HLA class I allele | Brain tissue block analyzed | % of pentamer-binding cells in the total CD8 population | CMV | Influenza A virus |
|---------------------------------|-----------------------------|--------------------------------------------------------|-----|------------------|
|                                 |                             | EBV          | Sum of % of EBV pentamer-binding cells<sup>a</sup> | EBNA3A + BZLF1<sup>b</sup> | pp65 | IE1 | MP | NP | MBP |
|                                 |                             | EBNA3A | EBNA3C | LMP1 | LMP2 | BZLF1 | BRLF1 | BMRF1 | BMLF1 | BALF4 |     |
| MS79 A*0201                     | A3B5                        | 0.9      | 1.0   | 1.7  | 3.6  | 0.3   | 0     | 0     |
|                                 | A1D5                        | 1.3      | 0.8   | 0.8  | 1.7  | 5.7   |       |       |
|                                 | A1B4                        | 2.7      | 1.8   | 1.7  | 1.8  | 0.7   | 8.7   |       |
| MS286 A*0201                    | A1A3                        | 0.0      | 0.0   | 0.0  | 0.0  | 0.0   | 0     | 0     |
|                                 | A1C1                        | 0.0      | 0.0   | 0.0  | 0.0  | 0.0   |       |       |
| MS330 B*0702                    | A6A1                        | 1.9      | 1.0   | 0.6  | 3.5  | 0     | 0     |       |
| MS356 B*0702                    | A3B4                        | 1.0      | 0.8   | 0.0  | 1.8  | 0     | 0     |       |
| MS289 A*0201 B*0702             | A1A2                        | 2.0      | 3.5   | 1.7  | 4.1  | 0     | 19.2  | 0     |
|                                 | A2E3                        | 0.0      | 0.0   | 0.0  | 0.0  | 0     |       |       |
| MS342 B*0702                    | P1C1                        | 0.2      | 0.3   | 1.0  | 0.4  | 0.5   | 3.6   | 0     |
|                                 | P2B7                        | 0.2      | 0.5   | 0.8  | 0.4  | 0.5   | 3.6   | 0     |
| MS92 B*0801                     | A5B2                        | 0.5      | 0.5   | 2.2  | 0.5  | 2.7   | 0.2   |       |
| MS154 B*0801                    | P3D4                        | 0.2      | 0.2   | 2.7  | 0.2  | 2.9   | 0     |       |
| MS180 B*0801                    | P2B7                        | 0.2      | 0.2   | 3.1  | 0.2  | 3.1   | 0.2   |       |
|                                 | P3D4                        | 0.4      | 0.4   | 1.7  | 0.4  | 1.7   | 0     |       |
| MS234 B*0801                    | P4C3                        | 1.6      | 1.6   | 3.5  | 1.6  | 5.1   | 0.2   |       |
|                                 | A2E3                        | 0.0      | 0.0   | 0.0  | 0.0  | 0     |       |       |
| MS352 B*0801                    | P1B5                        | 1.8      | 1.8   | 1.8  | 1.8  | 1.8   | 1.8   |       |
|                                 | P5C3                        | 0.1      | 0.1   | 0.1  | 0.1  | 0.1   | 0.1   |       |

<sup>a</sup>The figures in this column were obtained by summing the percentages of cells binding different EBV protein-derived peptides in serial sections from the same brain tissue block.

<sup>b</sup>The figures in this column represent the percentages of pentamer-binding cells in brain sections incubated simultaneously with EBNA3A/B*0801 and BZLF1/B*0801 pentamers.

<sup>c</sup>NA, not assessable.
Localization of CD8 T cells specific for EBV latent proteins in MS brain sections. Cells binding pentamers coupled with peptides from different EBV latent proteins were visualized in bright field in brain sections from HLA-A*0201-, B*0702-, and B*0801- MS donors. (A to C, donor MS356, B*0702+) Presence of CD8 T cells specific for B*0702-restricted EBNA3A (A) and EBNA3C (B) peptides, but not for B*0702-restricted CMV pp65 peptide (C), in the inflamed meninges; the insets show the cells indicated by the arrows in panels A and B at high-power magnification. (D to F, donor MS289, A*0201+/B*0702+) Perivascular CD8 T cells specific for B*0702-restricted EBNA3C peptide are indicated by the arrows in panels D and E and shown at high-power magnification in the insets. (F) Absence of CD8 T cells specific for A*0201-restricted CMV pp65 peptide in a meningeal infiltrate. (G to I, donor MS79, A*0201+) Presence of CD8 T cells specific for A*0201-restricted LMP1 peptide (G to I, arrows; the insets in panel G show the cells indicated by the arrowheads at high-power magnification) and LMP2 peptide (J and K, arrows) in the meninges where numerous scattered CD8 T cells are also detected (L). In adjacent sections, one CD8 T cell specific for A*0201-restricted CMV pp65 peptide (M; the inset shows the cell indicated by the arrow at high-power magnification) but no CD8 T cells specific for A*0201-restricted influenza A MP peptide (N) or cells binding B*0801/BZLF1 pentamer (O) were detected. Nuclei were stained with hematoxylin. Bars, 100 μm (C, L, and O), 50 μm (A, B, D, F to K, M, and N), 20 μm (E and inset in panel M), and 10 μm (insets in panels A, B, D, E, G, and K).
FIG 5 Localization of CD8 T cells recognizing EBV lytic proteins in MS brain sections. Cells binding pentamers coupled with peptides from different EBV lytic proteins were visualized in bright field in brain sections from HLA-A*0201<sup>+</sup>, B*0702<sup>+</sup>, and B*0801<sup>+</sup> MS donors. (A to H, donor MS79, A*0201<sup>+</sup>) CD8 T cells specific for A*0201-restricted BRLF1 peptide in WM (A) and meninges (B; the inset shows the cell indicated by the arrow at high-power magnification) but no staining in the meninges with mismatched B*0801/EBNA3A pentamer (C). Perivascular CD8 T cells specific for A*0201-restricted BMLF1 peptide (D and E) among infiltrating CD8 T cells (F) but no cells binding mismatched B*0801/EBNA3A pentamer (G) in a WM lesion. (H) Isolated CD8 T cells specific for A*0201-restricted BALF4 peptide in the meninges. (I to K, donor MS289, A*0201<sup>+</sup>/B*0702<sup>+</sup>) Several CD8 T cells specific for B*0702-restricted BMRF1 peptide scattered in an active WM lesion (I and J; the inset in panel J shows the cell indicated by the arrow at high-power magnification) and one CD8 T cell specific for A*0201-restricted BMLF1 peptide in the meninges (K). (L and M, donor MS342, A*0201<sup>+</sup>/B*0702<sup>+</sup>) Isolated CD8 T cells specific for B*0702-restricted BMRF1 peptide (L) and A*0201-restricted BALF4 peptide (M) in the meninges. (N and O) (MS234, B*0801<sup>+</sup>) Incubation of brain sections with pooled B*0801/EBNA3A and B*0801/BZLF1 pentamers reveals several pentamer-binding cells scattered throughout an active WM lesion (N; the inset shows the cell indicated by the arrow at high-power magnification); staining of a serial section with anti-CD8 MAb shows widespread CD8 T cell infiltration of the same WM lesion. Nuclei were stained with hematoxylin in panels A to E, H, and J to O. Bars, 100 μm (C and O), 50 μm (B, E to H, K, L, and N), 20 μm (A, D, I, J, M, and inset in panel B), and 10 μm (inset in panels J and N).
These data suggest that EBV-specific CD8 T cells account for a substantial proportion of CNS-infiltrating CD8 T cells.

**CD8 T cells recognizing common viruses and MBP are less frequent than EBV-reactive CD8 T cells or are undetectable in the MS brain.** We then asked whether CD8 T cells specific for immunodominant proteins of other common viruses, like CMV and influenza A virus, or the putative CNS autoantigen MBP could be visualized in the MS brain and if their frequency differed from that of EBV-specific T cells. CD8 T cells recognizing CMV were searched in brain samples from 12 MS donors using HLA-A*0201 and HLA-B*0702 pentamers conjugated with two different peptides from pp65, the major CMV structural protein, and HLA-B*0801 pentamers conjugated with a peptide from IE1, a major CMV immediate-early protein (Table 2). CMV-specific CD8 T cells were detected in brain sections from 4 of 12 MS donors (Fig. 4C, F, and M), accounting for 0.2 to 0.3% of the total CD8 population (Table 3). No influenza A virus-specific CD8 T cells were detected in brain sections from 6 MS donors (Table 3 and Fig. 4N) when HLA-A*0201 and HLA-B*0702 pentamers coupled to influenza A virus matrix protein (MP)- and nucleoprotein (NP)-derived peptides, respectively, were used (Table 2). In addition, no MBP-specific CD8 T cells were detected in brain samples from 4 HLA-A*0201+ MS donors (Table 3). The frequencies of CNS-infiltrating CD8 T cells recognizing CMV, influenza A virus, or MBP-derived peptides were always significantly lower than the frequencies of CD8 T cells recognizing EBV protein-derived peptides, both through all-HLA backgrounds (Fig. 7A) and by comparing the response to A*0201-, B*0702-, or B*0801-restricted epitopes (Fig. 7B to D).

**EBV-reactive CD8 T cells exhibit cytotoxic activity and contact EBV-infected cells in the MS brain.** Since polyfunctional CD8 T cells producing multiple inflamma-
tory cytokines and displaying cytotoxic activity are extremely effective in controlling viral infections, we sought to gain insights into the effector functions of CNS infiltrating EBV-specific CD8 T cells. In an initial set of experiments, brain sections from HLA-B*0801/H11001 MS donors were simultaneously labeled with EBV peptide-coupled pentamers (a mixture of EBNA3A/B*0801 and BZLF1/B*0801 pentamers) and antibodies to the proinflammatory cytokine gamma interferon (IFN-γ) or the lytic enzyme granzyme B, both of which are expressed by CD8 T cells infiltrating the MS brain [19, 35, 38, 53, 58, 59]. However, neither of these intracellular antigens could be visualized by immunofluorescence in fresh-frozen brain tissue (data not shown). Hence, to evaluate the cytotoxic function of EBV pentamer-binding cells, we performed double immunofluorescence stainings with the above-mentioned pentamers and a MAb specific for the degranulation marker CD107a. In agreement with previous data [35, 59], membrane expression of CD107a, a component of cytotoxic granules exposed on the cell surface after release of lytic granule contents, was observed in a proportion (approximately 15%; range, 7 to 20%) of CNS-infiltrating CD8 T cells (Fig. 8A to E). Furthermore, membrane CD107a staining was observed in virtually all cells binding pooled HLA-B*0801/EBNA-3A and HLA-B*0801/BZLF1 pentamers (Fig. 8G to J), indicating ongoing cytotoxic activity of EBV-specific CD8 T cells recognizing two highly immunodominant EBV antigens [62, 63].

We next asked whether EBV-specific CD8 T cells interact directly with EBV-infected cells in the MS brain. Due to technical reasons (i.e., incompatibility of tissue fixation and/or use of rabbit polyclonal antibodies to EBV antigens with the pentamer staining procedure), the only EBV antigen that could be analyzed in conjunction with the corresponding pentamer was the latent protein LMP2A. Staining of brain sections from

**FIG 7** Comparison of the frequencies of EBV-, CMV-, influenza A virus-, and MBP-specific CD8 T cells infiltrating the MS brain. The frequencies of CD8 T cells specific for viral protein- and MBP-derived peptides were compared irrespective of the HLA background (A) and in the same HLA background (A*B*0201 [B], B*0702 [C], or B*0801 [D]). Data are expressed as percentages of peptide-specific CD8 T cells in the total CNS-infiltrating CD8 population. P values were assessed by Kruskal-Wallis test with Dunn correction. The lines inside the boxes represent the median values; boxes extend from the 25th to the 75th percentile, covering the interquartile range (IQR), and whiskers extend from the 25th percentile, −1.5 IQR, to the 75th percentile, +1.5 IQR. Maximum outliers outside the whiskers are represented by individual marks.
one HLA-A*0201 MS donor (MS79) with antibodies to LMP2A and a mixture of A*0201/LMP2 356–364 and A*0201/LMP2 426–434 pentamers allowed us to visualize EBV-specific CD8 T cells contacting or juxtaposed to LMP2A/H11001 cells within the perivascular space of inflamed blood vessels in white matter lesions and in the meninges (Fig. 9A to C). Staining of brain sections from the same A*0201+ MS donor with pooled A*0201/LMP2 356–364, A*0201/LMP2 426–434, and A*0201/EBNA3C pentamers and anti-CD20 MAb also allowed us to visualize EBV-specific CD8 T cells contacting B cells (Fig. 9D and E). These observations suggest that encounter between EBV-specific CD8 T cells and infected B cells expressing the cognate viral antigen occurs in the MS brain, possibly leading to T-cell activation and killing of virus-infected cells.

**DISCUSSION**

The aim of this study was to test the hypothesis that EBV-specific CD8 T cells are involved in CNS tissue damage in MS by mediating an immunopathological response toward a persistent intracerebral EBV infection that was documented in previous studies performed in our (19, 35–39) and other (40–42) laboratories.

The key finding is that EBV-specific CD8 T cells are commonly found in the MS brain and are significantly more frequent than CMV-specific CD8 T cells. Furthermore, CD8 T cells recognizing influenza A virus or a putative CNS autoantigen are not detected. These data suggest that entry of EBV-specific CD8 T cells into the MS brain results from...
active recruitment rather than nonspecific extravasation due to the local inflammatory process. The findings obtained in MS brain tissue are in line with previous studies showing that CD8 T cells recognizing EBV, but not CMV or several candidate CNS autoantigens, accumulate in the CSF of MS patients (54–57). In a recent study performed in postmortem MS brain tissue (53), T cells, mainly CD8 T cells, recovered from WM lesions did not recognize nine candidate CNS autoantigens, including MBP, but did recognize autologous EBV-transformed B-cell lines; however, the cognate antigen, EBV or a B-cell-associated antigen, was not identified. Taken together with neuropathological evidence of active EBV infection in CNS-infiltrating B cells/plasma cells (19, 35–39, 42) and the predominance of CD8 T cells with a cytotoxic effector phenotype in the MS brain (50–53), the selective enrichment of EBV-specific CD8 T cells in postmortem MS brain samples reported here and in the CSF of MS patients (54–57) supports a pathogenic model of MS where skewed cytotoxic immune responses toward EBV may contribute to inflammation in the CNS. Failure to eradicate a chronic active EBV infection in the MS brain should lead to a vicious circle of viral antigens stimulating the anti-EBV immune response, which maintains local inflammation with devastating effects in a tissue with very limited regenerative capacity. In the context of chronic immune stimulation, a few EBV-specific CD8 T cells may be sufficient to amplify inflammation by activating macrophages and recruiting more antigen-specific as well as bystander T cells. This disease model is consistent with the notion that CD8 T cells are the main drivers of bystander tissue damage in EBV-associated immunopathologic diseases (7, 49). It also shows analogies with the pathogenesis of another inflammatory demyelinating disease of the CNS, human T-lymphotropic virus type 1 (HTLV-1)-associated myelopathy (HAM) or tropical spastic paraparesis, which is an infrequent complication of HTLV-1 infection (64). In HAM, circulating HTLV-1-infected T cells invade the CNS and trigger an immunopathologic response against the virus which damages neural cells (64). By analogy, MS could be considered a rare neurological complication of the most common EBV infection (4).

An EBV-centered pathogenic model of MS could also explain why B-cell-depleting
therapy, which is used in EBV-associated lymphoproliferative disease to eliminate EBV-transformed B cells, is highly effective in MS (24, 25, 32). In this disease, depletion of B cells by anti-CD20 MAbs would lower the viral burden and, consequently, the CNS-directed immunopathological response. Recently, we described profound EBV deregulation in the CNS and deep cervical lymph node, but not pulmonary lymph node, of a patient with primary progressive MS (65). We also observed a prominent proliferation of CD20-negative immunoblasts in the cervical lymph node paracortex, a finding indicative of T-cell activation (65). Although preliminary, these findings point to CNS-draining lymph nodes as the key site where an immunopathological response targeting intracerebral EBV is stimulated. Depletion of B cells supporting an active EBV infection in CNS-draining lymph nodes could explain the rapid therapeutic effect of anti-CD20 MAbs in MS despite low penetration in the CNS (66). The finding that rituximab causes depletion of B cells and a marked decline of T cells in the CSF of treated MS patients further suggests that EBV-infected B cells sustain pathogenic T cell responses (67, 68).

The second main finding of this study is that EBV antigen recognition by CNS-infiltrating CD8 T cells encompasses a wide range of proteins expressed in different phases of the EBV life cycle. These include nuclear (EBNA3A and EBNA3C) and membrane proteins (LMP1 and LMP2) expressed during EBV latency and BZLF1, BRLF1, BMLF1, BMRF1, and BALF4 proteins expressed during immediate-early, early, and late phases of the viral lytic cycle (6, 7). This finding is consistent with detection of a similarly wide range of EBV proteins and/or transcripts in postmortem MS brain samples, including EBNA2, EBNA3A, LMP1, LMP2A, BZLF1, BFRF1, BMRF1, gp350/220, and p160 (19, 35, 36, 39, 42, 58, 59). It should be stressed here that, analogous to the present study, EBV proteins and/or transcripts were detected in almost all MS brains analyzed when the samples included B-cell-containing immune infiltrates. The consistency of these findings corroborates the concept that intracerebral EBV infection and the CD8 T cell-mediated response to EBV play a role in MS pathogenesis.

A well-established hierarchy exists among CD8 T-cell responses that target EBV antigens. In particular, EBV latency III antigens EBNA3A/3B/3C are immunodominant, whereas the EBV latency II antigens, EBNA1/LMP1/LMP2A, are subdominant (62). EBV lytic cycle antigens also display a hierarchy of immunodominance, as the two immediate-early antigens, BRLF1 and BZLF1, and some early antigens elicit stronger responses than late lytic antigens (62, 63). In this study, no preferential CNS infiltration by CD8 T cells specific for the most immunodominant EBV protein-derived peptides was observed. However, CD8 T cells specific for EBV lytic proteins tended to be more frequent than those specific for EBV latent proteins, and CD8 T cells recognizing BZLF1 were significantly more frequent than those recognizing EBNA3A in the HLA-B*0801 background. Of interest, the frequency of CD8 T cells specific for EBV lytic antigens, including BZLF1, in the peripheral blood of patients with relapsing MS was higher during disease flares, while the CD8 T-cell response to EBV latent antigens increased during remissions (19). Since the MS brain samples analyzed in this study were characterized by a high degree of immune cell infiltration, it is plausible that more pronounced CNS inflammation is associated with a relatively higher frequency of EBV lytic antigen-specific CD8 T cells in brain tissue.

The third main finding of this study is that EBV-specific CD8 T cells recruited to the MS brain have a cytotoxic phenotype and contact EBV-infected cells. Cytotoxic activity revealed by perforin, granzyme B, and membrane CD107a immunostainings, as well as tight contacts with EBV-infected cells, was previously demonstrated for MS brain-infiltrating CD8 T cells (19, 35, 38, 58, 59). For technical reasons, in this study only expression of membrane CD107a in the subpopulation of EBV-specific CD8 T cells and contacts between EBV latently infected cells expressing LMP2A- and LMP2-specific CD8 T cells were investigated. The results suggest that EBV-specific CD8 T cells infiltrating the MS brain become activated after recognition of their cognate antigen on EBV-infected cells and kill their target cells. However, it is likely that not all encounters between CNS-infiltrating EBV-specific CD8 T cells and EBV-infected cells lead to elimi-
plementation of the latter. Because EBV-encoded proteins and viral microRNAs have immune evasion functions (69, 70), the cytotoxic response could fail to fully control intracerebral EBV infection, thereby perpetuating inflammation. It is also known that the T-cell-inhibitory molecule PD-L1 is upregulated by EBV latent proteins and may inhibit the immune response to EBV+ tumors (71–73). Further experiments are needed to establish if PD-L1 is expressed on EBV-infected B cells in the MS brain and plays a role in suppressing the local activation of PD-1+ cytotoxic T cells (53, 74).

If EBV is the main antigenic stimulus promoting immune-mediated inflammation in MS, it should be possible to treat MS by normalizing the EBV-host balance with antiviral drugs or T-cell therapy. Previous trials with antitherpesvirus drugs in MS did not show any significant improvement in clinical and radiological parameters but highlighted a possible effect in a subgroup with high disease activity (75). Interestingly, a recent study described the case of an HIV-negative patient with relapsing-remitting MS who achieved significant and sustained disease improvement upon treatment with zidovudine/lamivudine (Combivir), a highly active antiretroviral therapy (76). It was suggested that the beneficial response to zidovudine/lamivudine is related to the action of zidovudine, a known inhibitor of EBV lytic DNA replication (77). Based on the assumption that defective CD8+ T-cell immunity to EBV leads to CNS colonization by EBV-infected autoreactive B cells (21, 22), adoptive immunotherapy with in vitro-expanded autologous T cells directed against EBV latent proteins was recently used to treat MS patients (78). In a phase I trial in progressive MS, EBV-specific immunotherapy had no adverse effects, but the therapeutic efficacy of this treatment has to be evaluated in larger clinical trials (78).

The association between MS and the B-lymphotropic EBV is one of the best documented pathogen-chronic disease associations (4, 5, 10, 11), leading to the possibility that prevention or reduction of the risk to develop MS could be achieved with EBV vaccines (79, 80). To date, any theory of MS pathogenesis must explain the following, undisputed observations: increased MS risk after infectious mononucleosis; elevated immune reactivity to EBV, but not to any other tested pathogen; CD8 T cell predominance in the CNS inflammatory infiltrates; and high therapeutic efficacy of B-cell-depleting anti-CD20 MABs. The present study offers a possible explanation for these phenomena and a rationale for current and future treatments for MS.

MATERIALS AND METHODS

Brain tissues and sample selection. Postmortem frozen tissue blocks (about 4 cm³ each) from the cerebral hemispheres of persons with MS were obtained from the UK MS Society Tissue Bank at Imperial College London. Use of postmortem human tissues for research purposes was approved by the Ethics Committee of the ISS. Information on donors’ HLA class I alleles was obtained through the UK Multiple Sclerosis Tissue Bank for samples included in a previous MS genome-wide association study (81). For 11 donors, HLA genotypes were identified by HLA sequencing-based typing (Abbott Molecular) of brain-derived DNA; genomic DNA was extracted from MS brain tissue (15 to 20 mg) using a QIAamp DNA minikit (Qiagen, Valencia, CA) by following the manufacturer’s instructions.

Thirty-six snap-frozen brain tissue blocks from 24 MS cases who died in the progressive phase of MS and carried MHC class I alleles, enabling analysis of in situ pentamer binding using commercially available pentamers (Pro5 MHC class I pentamers; ProImmune, Oxford, UK), were included in a preliminary screening to select samples with good tissue preservation and substantial immune cell infiltration. For neuropathological assessment, brain sections (10 µm) were stained as described previously (19, 35, 36, 38). The extents of demyelination and lesion inflammatory activity were evaluated by immunostaining for myelin-oligodendrocyte glycoprotein (MOG) (kind gift of S. Piddlesden, Cardiff, UK) and MHC class II molecules, respectively (19, 35, 36). The degree of leucocyte infiltration in the meninges and white matter was evaluated using hematoxylin and eosin (H&E) staining and by immunohistochemistry using antibodies to B-cell (CD20 and CD79α), plasma cell (IgA, IgG, and IgM), and T-cell (CD8) markers (19, 35, 36, 38). The presence of degranulating CD8 T cells was assessed by double immunofluorescence for CD8 and CD107a, as described previously (35). After extensive neuropathological characterization, 18 brain blocks from 12 MS donors were selected for this study (Table 1). Based on the available clinical documentation, no immunotherapy was reported in the 6 months before death. HLA class I allele restriction, demographic and clinical data of the MS donors included in this study, and postmortem delay of brain tissue collection are shown in Table 1.

EBV detection. EBER in situ hybridization was performed using the PNA probe, which hybridizes with both EBER1 and EBER2, and the detection kit from DakoCytomation (Glostrup, Denmark), as described previously (35, 37).
Immunohistochemical stainings for EBV latent (EBNA2) and lytic (BZLF1) proteins and double immunofluorescence stainings for LMP1 and the B-cell marker CD79a and for BZLF1 and the plasma cell marker IgA, IgG, and IgM were performed in sections from paraformaldehyde (PFA)-fixed frozen brain tissue blocks of three MS donors analyzed in this study (MS79, MS92, and MS121), as previously described (19, 35–38). For double immunofluorescence staining for LMP1 and LMP2A, brain sections were incubated with anti-LMP2A rat MAb (1:50; clone TP4E11; Ascenion, Munich, Germany) and anti-LMP1 mouse MAb (1:100; clone CS.1-4; DakoCytomation) in phosphate-buffered saline (PBS) containing 1% bovine serum albumin overnight at 4°C, and, after washing with a mixture of Alexa Fluor 488-conjugated donkey anti-mouse IgA (Invitrogen, Eugene, OR) and tetramethylrhodamine (TRITC)-conjugated donkey anti-rat Ig (Jackson Immunoresearch Laboratories, Cambridgeshire, UK), both diluted 1:300 in PBS containing 3% normal donkey serum. After further washings, sections were mounted with antifade mounting medium containing 4',6-diamidino-2-phenylindole (DAPI) (Invitrogen).

**In situ pentamer staining.** Each snap-frozen brain tissue block was cut in series of twenty 10-μm sections with a cryostat; sections were air dried for 12 h at room temperature (RT) and stored at –80°C for no longer than 4 weeks. The first, the tenth, and the last sections of each consecutive series were stained with anti-CD8 MAb (DakoCytomation) and were used for quantification of CD8 T cells. The other sections were used to investigate pentamer binding. In situ pentamer stainings were performed in bright field using R-phycocerythrin (R-PE)-labeled Pro5 MHC class I pentamers (Proimmune) by following the manufacturer’s instructions, with minor modifications. Air-dried, frozen brain sections were maintained at RT for 90 min, rehydrated with 3 washes (2 min each) in PBS, and incubated with 10% normal goat serum (NGS) (Sigma-Aldrich, St. Louis, MO) for 30 min. Sections were then incubated overnight at 4°C with HLA class I pentamers (diluted 1:5 in PBS, final concentration of 10 μg/ml). In some experiments, brain sections were incubated with a mixture of two EBV pentamers. After extensive washing, sections were fixed in 2% PFA at RT for 15 min and then, after washing in PBS, were incubated overnight with rabbit anti-R-PE polyclonal antibody (1:400 in PBS containing 5% NGS) (GeneTex Inc., Irvine, CA). After washing in PBS, sections were incubated in PBS containing 0.1% H2O2 for 20 min in the dark to quench the endogenous peroxidase activity and then with biotinylated goat anti-rabbit IgG (1:300 in PBS containing 3% NGS) (Jackson Immunoresearch Laboratories) for 1 h at RT, followed by avidin-biotin horseradish peroxidase complex using the ABC Vectastain elite kit (Vector Laboratories, Burlingame, CA) for 1 h. The staining reaction was performed with 3,3'-diaminobenzidine (Sigma-Aldrich) as the chromogen. Negative controls included the use of HLA-A or HLA-B mismatched pentamers and omission of anti-R-PE polyclonal antibody. Sections were counterstained with hematoxylin, dehydrated in ethanol, sealed with Canadian balsam, and viewed under an Axioskop microscope (Carl Zeiss, Jena) equipped with a digital camera (AxioCam MRC); images were acquired using AxioVision 4 AC software.

For double immunofluorescence stainings with EBV peptide-coupled HLA class I pentamers and antibodies to CD8, CD20, CD107a, or LMP2A, brain sections were incubated with one or more pentamers and, after fixation with 2% PFA and washing in PBS, with a mixture of rabbit anti-R-PE polyclonal antibody and one of the following MAb: anti-CD8 mouse MAb (1:50; clone C8/144B; DakoCytomation), anti-CD20 mouse MAb (1:50; clone L26; DakoCytomation), anti-CD107a mouse MAb (1:150; clone H4A3; BD Bioscience, San Jose, CA), and anti-LMP2A rat MAb (1:50) in PBS with 5% NGS. After extensive washing in PBS, sections were incubated with a mixture of biotinylated goat anti-rabbit Ig and Alexa Fluor 488-conjugated goat anti-mouse or donkey anti-rat IgG (Invitrogen) diluted 1:100 in PBS containing 3% NGS or donkey serum and then with TRITC-conjugated streptavidin (Jackson Immunoresearch Laboratories). After further washings, sections were mounted with antifade mounting medium containing DAPI. Sections were analyzed and images acquired with a digital epifluorescence microscope (Leica Microsystems, Wetzlar, Germany). Negative-control stainings were performed using mismatched pentamers and Ig isotype controls or rabbit preimmune serum.

**Cell counts.** Following careful microscopic examination of brain sections, CD8<sup>+</sup> cells and pentamer-binding cells were counted in bright field in the whole section area (median value, 3 cm<sup>2</sup>; range, 2.5 to 4.4 cm<sup>2</sup>) with a Plan-Neofluor 20× objective. The percentage of pentamer-binding cells in the total population of brain infiltrating CD8<sup>+</sup> cells was calculated by dividing the number of pentamer-binding cells counted in a given section by the total number of CD8<sup>+</sup> cells counted in a serial section that was no more than 5 sections apart.

**Statistical analysis.** For univariate analyses, Mann-Whitney U test (for unpaired data) was used. Multiple independent variables were analyzed by Kruskal-Wallis test with the Dunn-Bonferroni post hoc correction for multiple testing. Analyses were performed using IBM SPSS Statistics 25 software.

**ACKNOWLEDGMENTS**

This study was funded by the Fondazione Italiana Sclerosi Multipla (grant 2016/R/27 to B.S.) and the Italian Ministry of Health (grant RF-2011-02347228 to F.A.). The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Brain postmortem tissue samples and the associated clinical and genetic data were supplied by the Multiple Sclerosis Society Tissue Bank (https://www.mssociety.org.uk/research/explore-our-research/research-we-fund/search-our-research-projects/ms-society-tissue-bank). We appreciate critical reviews of the manuscript by Pankaj Trivedi and Eleni Anastasiadou, Sapienza University, Rome.

B.S. contributed to study design and data acquisition, analysis, and interpretation;
REFERENCES
1. Compston A, Coles A. 2008. Multiple sclerosis. Lancet 372:1502–1517. https://doi.org/10.1016/S0140-6736(08)6087-7
2. Olsson T, Barcellos LF, Alfdorss L. 2017. Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis. Nat Rev Neurol 13:25–36. https://doi.org/10.1038/nrneurol.2016.187
3. Baranzini SE, Oksenberg JR. 2017. The genetics of multiple sclerosis: from 0 to 200 in 50 years. Trends Genet 33:960–970. https://doi.org/10.1016/j.tig.2017.09.004
4. Ascherio A. 2013. Environmental factors in multiple sclerosis. Expert Rev Neurother 13:3–9. https://doi.org/10.1586/14737375.2013.865866
5. Lucas RM, Hughes AM, Lay ML, Ponsonby AL, Dwyer DE, Taylor BV, Pender MP. 2011. Epstein-Barr virus and multiple sclerosis. J Neurol Neurosurg Psychiatry 82:1142–1148. https://doi.org/10.1136/jnnp.2011-300174
6. Thorley-Lawson DA. 2015. EBV persistence—introducing the virus. Curr Top Microbiol Immunol 390:151–209. https://doi.org/10.1007/978-3-319-22822-8_8
7. Taylor GS, Long HM, Brooks JM, Richardson AB, Hislop AD. 2015. The immunology of Epstein-Barr virus-induced disease. Annu Rev Immunol 33:787–821. https://doi.org/10.1146/annurev-immunol-032414-112326
8. Sumaya CV, Myers LW, Ellison GW, Ench Y. 1985. Increased prevalence and titer of Epstein-Barr virus antibodies in patients with multiple sclerosis. Ann Neurol 17:371–377. https://doi.org/10.1002/ana.1040170412
9. Lünenmann JD, Hupke P, Roberts S, Brück W, Gätter J, Münz C. 2008. Broadened and elevated humoral immune response to EBNA1 in pediatric multiple sclerosis. Neurology 71:1035–1039. https://doi.org/10.1212/01.wnl.0000326567.91097.87
10. Pakpooj J, Giovannoni G, Ramagopalan SV. 2013. Epstein-Barr virus and multiple sclerosis: association or causation? Expert Rev Neurother 13:287–297. https://doi.org/10.1586/er.13.68
11. Handel AE, Williamson AJ, Disanto G, Handunnetthi L, Giovannoni G, Ramagopalan SV. 2010. An updated meta-analysis of risk of multiple sclerosis following infectious mononucleosis. PLoS One 5:e12496. https://doi.org/10.1371/journal.pone.0012496
12. Levin LI, Munger KL, O’Reilly EJ, Falk KI, Ascherio A. 2010. Primary infection with the Epstein-Barr virus and risk of multiple sclerosis. Ann Neurol 67:824–830. https://doi.org/10.1002/ana.21978
13. Sundström P, Juto P, Wadell G, Hallmans G, Svenningsson A, Nyström L, Martin R. 2006. Increased frequency and broadened specificity of latent Epstein-Barr virus immunodominant epitopes in patients with multiple sclerosis. Acta Neurol Scand 133:1–24. https://doi.org/10.1038/cti.2016.87
14. Jilek S, Schluep M, Harari A, Canales M, Lysandsopoulos A, Zekeridou A, Pantaleo G, Du Pasquier RA. 2012. HLA-B7-restricted EBV-specific CD8 T cells are dysregulated in multiple sclerosis. J Immunol 188:4671–4680. https://doi.org/10.4049/jimmunol.1103100
15. Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Ramanom K, Selmay K, Traboulsi S, Aauter A, Masser M, Fontoura P, Belachew S, Garra H, Mairon N, Chinn P, Wolinsky JS, ORATORIO Clinical Investigators. 2017. Ocrelimub versus placebo in primary progressive multiple sclerosis. N Engl J Med 376:209–220. https://doi.org/10.1056/NEJMoa1604648
16. Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Ramanom K, Selmay K, Traboulsi S, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garra H, Kappos L, OPERA I and ORA I Clinical Investigators. 2017. Ocrelimub versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med 376:221–234. https://doi.org/10.1056/NEJMoa1601277
17. Sheridan C. 2015. Anti-CD20 antibody wows in multiple sclerosis. Nat Biotechnol 33:1215–1216. https://doi.org/10.1038/nbt.3101
18. Baker D, Pryce G, Amor S, Giovannoni G, Schmierer K. 2018. Learning from other autoimmunities to understand targeting of B cells to control multiple sclerosis. Brain 141:2834–2847. https://doi.org/10.1093/brain/awy239
19. Lang HL, Jacobsen H, Ikemizu S, Andersson C, Harkos K, Madsen L, Hjorth P, Sondergaard L, Svejgaard A, Wucherpfennig K, Stuart DI, Bell JI, Jones EY, Fugger L. 2002. A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat Immunol 3:940–943. https://doi.org/10.1038/nn1085
20. Lünenmann JD, Jelicic I, Roberts S, Lutteroti A, Ackenberg B, Martin R, Münz C. 2008. EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-gamma and IL-2. J Exp Med 205:1763–1773. https://doi.org/10.1084/jem.20072397
21. van Sechel AC, Bajramovic JJ, van Stipdonk MJ, Persoon-Deen C, Geurtsens SB, van Noort JM. 1999. EBV-induced expression and HLA-DR-restricted presentation by human B cells of alpha B-crystallin, a candidate autoantigen in multiple sclerosis. J Immunol 162:129–135.
22. Pender MP. 2003. Infection of autoreactive B lymphocytes with EBV, causing chronic autoimmune diseases. Trends Immunol 24:584–588. https://doi.org/10.1016/j.it.2003.09.005
23. Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, Bar-Or A, Panza M, Sarkar N, Agarwal S, Langer-Gould A, Smith CH, HERMES Trial Group. 2008. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358:676–688. https://doi.org/10.1056/NEJMoa0706383
24. Tracy SI, Kakalacheva K, Lünenmann JD, Luzuriaga K, Mittendorf J, Thorley-Lawson DA. 2012. Persistence of Epstein-Barr virus in self-reactive memory B cells. J Virol 86:12330–12340. https://doi.org/10.1128/JVI.01699-12
25. Panikkar A, Smith C, Hislop A, Tellung N, Dasari V, Hogquist KA, Wykes M, Moss DJ, Rickinson A, Balfour HH, Jr, Khanna R. 2015. Impaired Epstein-Barr virus-specific neutralizing antibody response during acute infec-
tious mononucleosis is coincident with global B-cell dysfunction. J Virol 89:9137–9141. https://doi.org/10.1128/JVI.01293-15.

35. Serafini B, Rosiccarelli B, Franciotta D, Magliozzi R, Reynolds R, Cirpe, A, Andreoni L, Trivedi P, Valentini V, Faggioni A, Aloisi F, Fiol 2007. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med 204:2899–2912. https://doi.org/10.1084/jem.20071030.

36. Serafini B, Severa M, Cumbel-Cazabas S, Rosiccarelli B, Veroni C, Chiappetta G, Magliozzi R, Reynolds R, Coccia EM, Aloisi F, Fiol 2010. Epstein-Barr virus latent infection and BAFF expression in B-cells in the multiple sclerosis brain: implications for viral persistence and intrathecal B-cell activation. J Neuroepathol Exp Neurol 69:677–693. https://doi.org/10.1093/jnep/sex322.

37. Serafini B, Muzio L, Rosiccarelli B, Aloisi F, 2013. Radioactive in situ hybridization for EBER supports presence of Epstein-Barr virus in the multiple sclerosis brain. Brain 136:e233. https://doi.org/10.1093/brain/awt315.

38. Magliozzi R, Serafini B, Rosiccarelli B, Chiappetta G, Veroni C, Reynolds R, Aloisi F, 2013. Epstein-Barr virus latent infection in inflammatory cortical lesions in secondary progressive multiple sclerosis. J Neuroepathol Exp Neurol 72:29–41. https://doi.org/10.1093/jnep/neo131.

39. Veroni C, Serafini B, Rosiccarelli B, Fagnani C, Aloisi F, 2018. Transcription profiling of Epstein-Barr virus in the brain of patients with multiple sclerosis. J Neuroinflammation 15:18. https://doi.org/10.1186/s12974-017-1049-5.

40. Tzartos JS, Khan G, Vossenkamper A, Cruz-Sadaba M, Lonardi S, Sefia E, van Nierop GP, Mitterreiter JG, van de Vijver DA, de Swart RL, Meier UC. 2012. Association of innate immune activation with latent Epstein-Barr virus infection in multiple sclerosis patients. Acta Neuropathol 134:383–401. https://doi.org/10.1007/s00401-017-1744-4.

41. Hassani A, Johansen JN, Vartdal F, Robins H, Jürate Saltbye B, Holmøy T, Olweus J. 2014. High-throughput sequencing of TCR repertoires in multiple sclerosis reveals intrathecal enrichment of EBV-reactive CD+ T cells. Eur J Immunol 44:3439–3452. https://doi.org/10.1002/eji.201444662.

42. Moreno MA, Or-Geva N, Aftab BT, Khanna R, Croze E, Steinman L, Han KC. 2009. Epstein-Barr virus infection is not a characteristic feature of the nervous system and cervical lymph node of a patient with primary progressive multiple sclerosis. J Exp Med 209:51–60. https://doi.org/10.1084/jem.192.3.393.

43. van Nierop GP, van Luijn JM, Michels SS, Melief MJ, Janssen M, Langerak AW, Ouwendijk WJD, Verjans G, Verjans GM. 2017. Phenotypic and functional characterization of T cells in white matter lesions of multiple sclerosis patients. Acta Neuropathol 134:838–41. https://doi.org/10.1007/s00401-017-1744-4.

44. Jaquiery E, Jilek S, Schluep M, Meylan P, Lyssandropoulos A, Panteleo G, Du Pasquier RA. 2010. Intrathecal immune responses to EBV in early MS. Eur J Immunol 40:878–887. https://doi.org/10.1002/eji.200939761.

45. Sargsyan SA, Shearer AJ, Ritchie AM, Burgoon MP, Anderson S, Hemmer AW, Ouwendijk WJD, Hintzen RQ, Verjans G. 2017. Phenotypic and Epstein-Barr virus infection status of laser-cut immune cells from the multiple sclerosis brain. J Exp Med 214:1247–1262. https://doi.org/10.1084/jem.192.3.393.

46. Torkildsen Ø, Stansberg C, Angelskår SM, Kooi EJ, Geurts JJ, van der Valk P, Amor S. 2010. Epstein-Barr virus latent infection and BAFF expression in B-cells in the multiple sclerosis brain. J Exp Med 209:51–60. https://doi.org/10.1084/jem.192.3.393.
of Epstein-Barr virus control innate and adaptive antiviral immunity. 
Journal of Virology 91:10822–10834. https://doi.org/10.1128/JVI.01667-16.

70. Ressing ME, van Gent M, Gram AM, Hooykaas MJ, Piersma SJ, Wiertz EJ. 2015. Immune evasion by Epstein-Barr virus. Curr Top Microbiol Immunol 391:355–381. https://doi.org/10.1007/978-3-319-22834-1_12.

71. Goodman A, Patel SP, Kurzrock R. 2017. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas. Nat Rev Clin Oncol 14:203–220. https://doi.org/10.1038/nrclinonc.2016.168.

72. Anastasiadou E, Stroopinsky D, Alimperti S, Jiao AL, Pyzer AR, Cippitelli M, Gaulard P, Babcock HJ, Zhang H, Zhou J, et al. 2019. Epstein-Barr virus: the path from association to causality. J Clin Invest 129:3861–3873. https://doi.org/10.1172/jci.insight.124714.

73. Trivedi P, Slack FJ, Anastasiadou E. 2018. Epstein-Barr virus: from kisses to cancer, an ingenious immune evader. Oncotarget 9:36411–36412. https://doi.org/10.18632/oncotarget.26381.

74. Cencioni MT, Magliozzi R, Nicholas R, Ali R, Malik O, Reynolds R, Borsellino G, Battistini L, Muraro PA. 2017. Programmed death 1 is highly expressed on CD8+CD57+ T cells in patients with stable multiple sclerosis and inhibits their cytotoxic response to Epstein-Barr virus. Immunology 152:660–667. https://doi.org/10.1111/imn.12808.

75. Lycke J. 2017. Trials of antivirals in the treatment of multiple sclerosis. Nat Rev Neurol 13:97–106. https://doi.org/10.1038/nrneurol.2017.1.

76. Drosu NC, Edelman ER, Housman DE. 2018. Could antiretrovirals be helpful in treating EBV in MS? A case report. Mult Scler Relat Disord 22:19–21. https://doi.org/10.1016/j.msard.2018.02.029.

77. Lin JC, Zhang ZX, Smith MC, Biron K, Pagano JS. 1988. Anti-human immunodeficiency virus agent 3’-azido-3’-deoxythymidine inhibits replication of Epstein-Barr virus. Antimicrob Agents Chemother 32:265–267. https://doi.org/10.1128/aac.32.2.265.

78. Pender MP, Csurhes PA, Smith C, Douglas NL, Neller MA, Matthews KK, Beagley L, Rehan S, Crooks P, Hopkins TJ, Blum S, Green KA, Ioannides 2A, Swayne A, Aftab BT, Hooper KD, Burrows SR, Thompson KM, Coulthard A, Khanna R. 2018. Epstein-Barr virus-specific T cell therapy for progressive multiple sclerosis. JCI Insight 3:124714. https://doi.org/10.1172/jci.insight.124714.

79. Sugden B. 2014. Epstein-Barr virus: the path from association to causality for a ubiquitous human pathogen. PLoS Biol 12:e1001939. https://doi.org/10.1371/journal.pbio.1001939.

80. Cohen JI. 2018. Vaccine development for Epstein-Barr virus. Adv Exp Med Biol 1045:477–493. https://doi.org/10.1007/978-981-10-7239-7_22.

81. International Multiple Sclerosis Genetics Consortium, Wellcome Trust Case Control Consortium 2, Sawcer S, Hellenthal G, Pirinen M, Spencer CCA, Patapolous NA, Moutsianas L, Dilthey A, Su Z, Freeman C, Hunt SE, Edkins S, Gray E, Booth DR, Potter SC, Goris A, Band G, Oturai AB, Strange A, Saarela J, Bellenguez C, Fontaine B, Gillman M, Hemmer B, Gwiliam R, Zipp F, Jayakumar A, Martin R, Leslie S, Hawkins S, Giannoulatos E, D’Alfonso S, Blackmon H, Martellini Boneschi F, Liddle J, Harbo HF, Perez ML, Spurkland A, Waller MJ, Mycko MP, Ricketts M, Comabella M, Hammond N, Kockum I, McCann OT, Pan M, Whittaker P, Kempinna P, Weston P, Haskins C, Widdas S, Zajicek J, Dronon S, Robertson N, Bumpstead SJ, Barcellos LF, Ravindrarajah R, Abraham R, Alfredsson L, Ardile K, Aubin C, Baker A, Baker K, Baranzini SE, Bergamaschi L, Bergamaschi R, Bernstein A, Berthele A, Boggild M, Bradfield JP, Brasset D, Broadley SA, Buck D, Buzukueven H, Capra R, Carroll WM, Cavalla P, Cellis EG, Cepok S, Chiavacci R, Clerget-Darpoux F, Clysters K, Comi G, Cossburn M, Dourn-Reibeix I, Cox MB, Cozen W, Cree BAC, Cross AH, Cusi D, Daly MJ, Davis E, de Bakker PIW, Debuverie M, D’hooghe MB, Dixon K, Dobosi R, Dubois B, Ellingshaus D, Elvaara I, Esposito F, Fontenille C, Foote S, Franke A, Galimberti D, Ghezzi A, Glanser J, Gomez R, Gout O, Graham C, Grant SFA, Guerin FR, Hakonarson H, Hall P, Hamsten A, Hartung H-P, Heard RN, Heath S, Hobart J, Hoshi M, Infante-Duarte C, Ingram G, Ingram W, Islam T, Jagodic M, Kabbesch M, Kenmoe AE, Kilpatrick TJ, Kim C, Klop N, Koivistio K, Larsson M, Lathrop M, Lechner-Scott JS, Leone MA, Leppä V, Lijjedahl U, Lomfom BL, Lincoln RR, Link J, Liu J, Lorentzen AR, Lupoli S, Maciardi F, Mack T, Marriott M, Martinelli V, Mason D, McCauley JL, Metcht F, Merlos I-L, Mihalova T, Montalban X, Mottershead J, Myhr K-M, Naldi P, Ollier W, Page A, Palotie A, Pelletier J, Piccillo L, Pickersgill T, Piel FH, Pobywajlo S, Quach HL, Ramsay HF, Reunanen M, Reynolds R, Rioux JD, Rodegher M, Roesner S, Rubio JP, Rücker I-M, Salvetti M, Salvi E, Santaniello A, Schafer CA, Schreiber S, Schulze C, Scott RJ, Selieberg F, Selmaj KW, Sexton D, Shen L, Simon-Acuna B, Skidmore S, Sleiman PMA, Smestad C, Sørensen PS, Søndergaard HB, Stankovich J, Strange RC, Sulonen A-M, Sundquist E, Syvänen A-C, Taddeo F, Taylor B, Blackwell JM, Tienari P, Bramon E, Tourbah A, Brown MA, Tronnolone Y, Tupper N, Turbridy NC, Evanso A-C, Varditza M, Velinik J, Wittig M, Tremblay RC, Tsai C, Turpin W, Tyler JA, Vukanac AC, Zhang H, Wood NW, Zuvich R, Deloukas P, Langford C, Duncanson A, Oksenberg JR, Pericak-Vance MA, Haines JL, Ollison T, Hilbert J, Iwamoto U, Galloway J, Hauser SL, McVean G, Donnelly P, Compston A. 2011. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 476:214–219. https://doi.org/10.1038/nature10251.